Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
574 Leser
Artikel bewerten:
(2)

AppViewX Appoints Former Ping Identity Executive Jason Bonds as Chief Revenue Officer to Extend Hyper Growth

Finanznachrichten News

Senior technology executive to lead go-to-market activities and strategic partnerships to drive new opportunities and further strengthen customer success

NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AppViewX, the leader in machine identity management and application delivery automation, today announced the appointment of Jason Bonds as the company's Chief Revenue Office (CRO). Jason will oversee revenue generation, customer and partner operations, and multi-channel go-to-market activities to accelerate global field operations across emerging and existing markets, including North America, EMEA and APJ.

AppViewX Appoints Former Ping Identity Executive Jason Bonds as Chief Revenue Officer to Extend Hyper Growth

AppViewX has experienced high-growth momentum and increased demand for its Machine Identity Management platform, as more enterprises take an identity-first approach to their overall security strategy. As machine identity usage expands dramatically to devices, clouds, containers and IoT, enterprises need automated governance solutions to avoid unplanned outages, meet compliance requirements and gain operational efficiencies. To support increased demand, the company will build out field operations with aggressive, additional hiring in North America, EMEA and APJ regions.

Jason joins the team with over 15 years of go-to-market leadership and several successful high-growth exits managing diverse, global teams. Prior to AppViewX, Jason was the CRO of Chainalysis where he led the company's Revenue and Marketing operations and was responsible for growing the company's ARR significantly, resulting in funding rounds that led to a $4.2B valuation. Prior to Chainalysis, Jason spent 11 years at Ping Identity where he was a key member of the management team that led to a successful IPO in 2019.

"I am very excited to have Jason join AppViewX and lead our global go-to-market and field operations," said Gregory Webb, CEO at AppViewX. "The Machine Identity Management space is exploding - especially with Gartner including Machine Identity Management as a top 10 Security and Risk trend for 2021. Jason's decade-long experience at Ping Identity helped him understand the critical role identity governance plays in today's security landscape. With his expert guidance and leadership, we'll continue to expand our global reach and meet increased demand through robust distribution channels."

AppViewX has cemented itself as a vital part of the IAM tool stack for leading enterprises, rapidly increasing its global customer base across multiple industries. AppViewX CERT+ was recently recognized by Gartner in the Solution Comparison for PKI and Certificate Management Tools, 2021 report

"There has never been a more pivotal time than now to join the AppViewX team and build on the momentum that made them a solution of choice for Machine Identity Management," said Jason Bonds, Chief Revenue Officer at AppViewX. "The opportunity in this space is endless. I am impressed with the impact created by AppViewX in helping customers, who are some of the world's largest enterprises, move faster, eliminate errors and reduce cost. I am eager to work alongside Gregory and the leadership team as we build together a strong mechanism to address the unprecedented global demand for Machine Identity Management solutions and further propel continued customer success."

AppViewX has been recognized as a Sample Vendor in the Gartner Hype Cycle for IAM 2021 for Machine Identity Management. Read the report to gain insight on how your organization would benefit from an org-wide strategy to manage IAM and Machine Identities.

About AppViewX:

AppViewX is a pioneer and leader in certificate and key lifecycle automation, Machine Identity Management, and IoT and DevOps security solutions. The AppViewX Platform is a modular software application that enables the automation and orchestration of network infrastructure using an intuitive, context-aware, visual workflow. It quickly and easily translates business requirements into automation workflows that improve agility, enforce compliance, eliminate errors, and reduce cost.

AppViewX customers are among the world's most demanding Fortune 1000 organizations in financial services and banking, healthcare, oil and gas, manufacturing, and high tech. Today, with Gartner Peer Insights rating of 4.9 out of 5, AppViewX automates NetOps, SecOps, and DevOps for six of the top ten global commercial banks, five of the top ten global media companies, and five of the top ten managed healthcare providers. AppViewX is headquartered in New York, U.S. with additional offices in U.K., Australia and three development centers of excellence in India. For more information, visit https://www.appviewx.com.

Photo: https://mma.prnewswire.com/media/1625361/Jason_Bonds.jpg

Logo: https://mma.prnewswire.com/media/1039633/AppViewX_Logo.jpg

AppViewX Logo
© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.